Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Emery

Showing results (41-50 of 140) with videos related to

Pageof 14
Sort By:
Plos One|October 20, 2017
HIV dynamics linked to memory CD4+ T cell homeostasisJohn M Murray, John Zaunders, Sean Emery, et al.
AIDS (London, England)|September 10, 2010
Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trialAllison Martin, Janaki Amin, David A Cooper, et al.
The Journal of Infectious Diseases|May 14, 2008
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up, Jens D Lundgren, Abdel Babiker, et al.
Controlled Clinical Trials|April 12, 2002
The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRITSean Emery, Donald I Abrams, David A Cooper, et al.
Therapeutic Drug Monitoring|September 28, 2017
Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 StudyAlieu B Amara, Laura J Else, Dianne Carey, et al.
AIDS (London, England)|September 10, 2003
Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitorsSunee Sirivichayakul, Kiat Ruxrungtham, Chaiwat Ungsedhapand, et al.
The Journal of Antimicrobial Chemotherapy|July 6, 2005
Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapyAlan Winston, Mark Bloch, Andrew Carr, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 22, 2019
Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm3: Findings From the Strategic Timing of AntiRetroviral Therapy (START) TrialJeffrey A Boatman, Jason V Baker, Sean Emery, et al.
Plos Clinical Trials|August 1, 2006
A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST studyGillian Hales, Chris Birch, Suzanne Crowe, et al.
Pharmacogenomics|May 25, 2019
Influence of <i>CYP3A5</i> and <i>SLCO1B1</i> polymorphisms on atazanavir/r concentrations in Thai HIV-infected patientsNoppaket Singkham, Anchalee Avihingsanon, Narukjaporn Thammajaruk, et al.
Pageof 14

Showing results (41-50 of 140) with videos related to

Sort By:
Pageof 14
Plos One|October 20, 2017
HIV dynamics linked to memory CD4+ T cell homeostasisJohn M Murray, John Zaunders, Sean Emery, et al.
AIDS (London, England)|September 10, 2010
Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trialAllison Martin, Janaki Amin, David A Cooper, et al.
The Journal of Infectious Diseases|May 14, 2008
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up, Jens D Lundgren, Abdel Babiker, et al.
Controlled Clinical Trials|April 12, 2002
The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRITSean Emery, Donald I Abrams, David A Cooper, et al.
Therapeutic Drug Monitoring|September 28, 2017
Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 StudyAlieu B Amara, Laura J Else, Dianne Carey, et al.
AIDS (London, England)|September 10, 2003
Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitorsSunee Sirivichayakul, Kiat Ruxrungtham, Chaiwat Ungsedhapand, et al.
The Journal of Antimicrobial Chemotherapy|July 6, 2005
Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapyAlan Winston, Mark Bloch, Andrew Carr, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 22, 2019
Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm3: Findings From the Strategic Timing of AntiRetroviral Therapy (START) TrialJeffrey A Boatman, Jason V Baker, Sean Emery, et al.
Plos Clinical Trials|August 1, 2006
A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST studyGillian Hales, Chris Birch, Suzanne Crowe, et al.
Pharmacogenomics|May 25, 2019
Influence of <i>CYP3A5</i> and <i>SLCO1B1</i> polymorphisms on atazanavir/r concentrations in Thai HIV-infected patientsNoppaket Singkham, Anchalee Avihingsanon, Narukjaporn Thammajaruk, et al.
Pageof 14